A Comparative Study of Delayed Endoscopic DTI and Autologous Flap Reconstruction Post-Mastectomy (DEDIA)
A National Multicenter, Prospective, Cohort Study on Delayed Endoscopic Direct-to-Implant Breast Reconstruction Via Transaxillary Approach Versus Autologous Flap Breast Reconstruction Following Mastectomy
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
This study is a multicenter, Prospective, randomized controlled trial. According to previous study results, the mean difference in Breast-Q breast satisfaction scores at one year postoperatively versus preoperatively was approximately 10.4 points in the autologous tissue breast reconstruction group. It is estimated that the delayed direct-to-implant breast reconstruction group will achieve a 10.4-point improvement in breast satisfaction scores one year after surgery. The difference in Breast-Q breast satisfaction scores between postoperative and preoperative assessments is non-inferior to that of autologous reconstruction. Based on historical data, the sample size was calculated for both groups, with the study hypothesis that the difference in Breast-Q breast satisfaction scores between postoperative and preoperative assessments in the delayed direct-to-implant breast reconstruction group is non-inferior to that of the delayed abdominal flap breast reconstruction group (non-inferiority margin = 3). Within each stratified group, the ratio of delayed direct-to-implant breast reconstruction group to abdominal flap reconstruction was set at 3:1. Using a one-sided test with a significance level of α = 0.05 and 80% statistical power, and assuming a 10% dropout rate, the total sample size required is 263. This includes 197 cases in the delayed direct-to-implant breast reconstruction group and 66 cases in the abdominal flap reconstruction group
1. Postoperative Surgical Complications: Assessed using Any Complication, Major Complication, and Minor Complication.
- Any Complication: Any complication related to the surgical procedure occurring postoperatively. Each occurrence in a subject counts as one event. Postoperative complications can be classified into Grades I-V according to the Clavien-Dindo classification system. Complications graded Clavien-Dindo III or higher are considered Major Complications.
- Major Complication: Defined as a complication related to the reconstructive procedure that persists despite observation and conservative management, requiring surgical intervention. Examples include wound dehiscence, hemorrhage requiring surgical intervention, surgical site infection, flap ischemia/necrosis, implant rupture, prosthesis loss, etc.
- Minor Complication: Defined as a complication that resolves with observation or conservative management alone, without requiring surgical intervention. Examples include hemorrhage controllable by compression, surgical site infection controllable by oral antibiotics, seroma after drain removal, arm lymphedema, localized skin flap or NAC (nipple-areolar complex) ischemia/necrosis resolving spontaneously, implant malposition correctable by manual manipulation, animation deformity due to pectoralis major muscle division, pectoralis major muscle spasm, etc.
2. Postoperative Aesthetic Outcomes and Quality of Life (QoL) Assessment: Evaluated using the following validated instruments: the BREAST-Q questionnaire (Reconstruction module), Ueda Scale, Harris Scale, QLQ-BR45 questionnaire, and SCAR-Q questionnaire.
3. Aesthetic Complication Assessment: Evaluated through assessment of capsular contracture, implant visibility/palpability (contour visibility), rippling, implant malposition/displacement, and the need for secondary surgery due to aesthetic concerns.
- Capsular Contracture (Baker Classification): A complication where the fibrous capsule surrounding the implant abnormally thickens, hardens, and contracts, leading to breast firmness, distortion, and/or pain.
- Rippling: The appearance of visible wrinkles or folds on the skin surface overlying the implant.
- Implant Visibility/Palpability (Contour Visibility): A phenomenon where the edge or shape of the implant becomes visibly apparent or readily palpable beneath the skin surface. Can be graded as mild, moderate, or severe.
- Implant Malposition/Displacement: Shifting of the implant from its intended position post-implantation, resulting in abnormal breast contour or asymmetry.
- Animation Deformity: Characterized by abnormal movement, contour distortion, or functional limitation of the breast mound during pectoralis muscle contraction (e.g., during arm movement).
- Pectoralis Major Muscle Pain: Pain localized to the region of the pectoralis major muscle.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Zhenggui Du
- Telefonnummer: +86 13880768222
- E-Mail: docduzg@163.com
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Female patients aged 18-70 years
- One year after Modified Radical Mastectomy (MRM), Nipple-Sparing Mastectomy (NSM), or Skin-Sparing Mastectomy (SSM), or six months after the completion of radiotherapy, provided the local skin remains viable and sufficiently lax;
- voluntary participation and ability to provide written informed consent.
Exclusion Criteria:
- History of breast surgery in which the pectoralis major muscle was removed;
- Patients with serious preoperative co-morbidities and poor general condition who cannot tolerate the surgery;
- Diabetes mellitus with a long history of smoking or combined poor glycemic control;
- current enrollment in other clinical trials that may interfere with study outcomes;
- Review (clinical, imaging, pathological basis) reveals the presence of local/regional recurrence or uncontrollable distant metastasis.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
delayed Autologous Flap Breast Reconstruction
·DIEP Flap (Deep Inferior Epigastric Perforator Flap) The DIEP flap uses skin and fat from the lower abdomen but preserves the rectus abdominis muscle. Only the tiny perforating blood vessels (deep inferior epigastric artery and vein) that pass through the muscle are dissected and taken with the flap. These vessels are then reconnected to vessels in the chest (usually internal mammary vessels) under a microscope. Advantages: Minimal abdominal wall morbidity; lower risk of bulge or hernia; faster recovery of core strength. ·TRAM Flap (Transverse Rectus Abdominis Myocutaneous Flap) The TRAM flap also uses lower abdominal tissue, but it includes a segment of the rectus abdominis muscle (either pedicled or free). In the pedicled version, the muscle with its overlying skin/fat is tunnelled under the skin up to the chest, relying on the superior epigastric vessels. In the free TRAM, the muscle is detached and reattached to chest vessels like a DIEP. |
|
delayed Endoscopic DTI Breast Reconstruction
This technique, developed as an original procedure by our team, is performed through an axillary incision using a gas-inflated endoscopic approach.
It breakthroughly integrates the traditional two-stage operation into a single-stage procedure.
First, the retropectoral plane is dissected using a reverse-sequence technique.
Postoperatively, intentional fluid accumulation within the implant pocket is utilized to expand the skin envelope.
This achieves significantly greater tissue expansion compared to conventional tissue expanders, resulting in a reconstructed breast with a more natural contour and softer tissue consistency.
Second, the entire procedure strategically avoids creating any new incisions within the breast region itself.
This significantly reduces the risk of wound dehiscence and surgical site infection while shortening the postoperative recovery period.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
breast satisfaction
Zeitfenster: 1 year
|
Compare the BREAST-Q score(The psychosocial well-being, satisfaction with breasts, satisfaction with sexual life, and physical well-being of the chest from the BREAST-Q questionnaire's breast reconstruction module were used for evaluation.
The BREAST-Q scoring system converts each patient's performance across these domains into independent scores ranging from 0 to 100, with higher scores indicating better health-related quality of life or satisfaction in the corresponding domain.)
|
1 year
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Operative time
Zeitfenster: during operation
|
duration from skin incision to completion of wound closure
|
during operation
|
|
surgical-related costs
Zeitfenster: during operation
|
includes all direct medical expenses incurred during the operation
|
during operation
|
|
Complication outcomes
Zeitfenster: 3 months and 1 year postoperatively between the two groups.
|
Surgical complication rates, including flap scald, NAC ischemia/necrosis, seroma, surgical area infection, bleeding, incision splitting, flap ischemia/necrosis
|
3 months and 1 year postoperatively between the two groups.
|
|
Doctor-report outcomes
Zeitfenster: Intraoperative, 3 months, 1 year postoperatively
|
-The Ueda scale is independently assessed by three professional healthcare workers across multiple domains, including breast size symmetry, breast shape symmetry, scar visibility, nipple-areola complex (size symmetry, position symmetry, color consistency), and inframammary fold position symmetry.
Individual items are scored from 0 to 2 points, with a total score ranging from 0 to 10. Higher scores indicate better postoperative aesthetic outcomes: a total score of ≥9 is considered excellent, 7-8 good, 5-6 fair, and ≤4 poor.
|
Intraoperative, 3 months, 1 year postoperatively
|
|
patient-report outcomes(Harris scale)
Zeitfenster: Intraoperative, 3 months, 1 year postoperatively
|
It consists of four grades: Excellent (bilateral breasts essentially symmetric both with and without a bra), Good (symmetric when wearing a bra but obviously asymmetric without a bra), Fair (asymmetric but not obvious even when wearing a bra), and Poor (one breast destroyed or bilateral breasts obviously asymmetric).
Higher scores indicate better aesthetic outcomes.
|
Intraoperative, 3 months, 1 year postoperatively
|
|
patient-report outcomes (SCAR-Q scale)
Zeitfenster: Intraoperative, 3 months, 1 year postoperatively
|
a patient-reported questionnaire consisting of 12 items, scoring only the scar on the operated side.
Higher scores indicate better aesthetic outcomes.
|
Intraoperative, 3 months, 1 year postoperatively
|
|
patient-report outcomes (The QLQ-BR45 scale )
Zeitfenster: Intraoperative, 3 months, 1 year postoperatively
|
assesses quality of life in breast cancer patients, including both core cancer and breast cancer-specific dimensions.
It covers 4 functional domains, 9 symptom domains, and 6 single items/symptoms.
The scale uses a 4-point Likert response (1="Not at All" to 4="Very Much").
Domain scores are linearly converted to a 0-100 scale; higher scores indicate better quality of life for functional domaTime Frame: Intraoper
|
Intraoperative, 3 months, 1 year postoperatively
|
|
Aesthetic complications
Zeitfenster: 1 years postoperatively
|
Capsular contracture (Baker Grade); Implant visibility/palpability (contour visibility); Rippling; Implant malposition/displacement; Animation deformity; Pectoralis major muscle pain;
|
1 years postoperatively
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2025(1491)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .